Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis.
Blood Adv
; 8(3): 549-552, 2024 02 13.
Article
in En
| MEDLINE
| ID: mdl-38091577
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, B-Cell, Marginal Zone
Limits:
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
Blood Adv
Year:
2024
Document type:
Article
Country of publication: